Cargando…

Meta-Analysis of Randomized Controlled Trials on Androgens versus Erythropoietin for Anaemia of Chronic Kidney Disease: Implications for Developing Countries

Androgens which are relatively cheap were used in the treatment of anaemia in dialysis patients before the advent of Erythropoietin (EPO). However, there are concerns about their efficacy and side effects. Aims. To examine the efficacy and harms of androgens for the treatment of anaemia of chronic k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adamu, B., Ma'aji, S. M., Erwin, P. J., Tleyjeh, I. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479968/ https://www.ncbi.nlm.nih.gov/pubmed/23119160 http://dx.doi.org/10.1155/2012/580437

Ejemplares similares

Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial
por: Johnson, David Wayne, et al.
Publicado: (2008)

Erythropoietin, uncertainty principle and cancer related anaemia
por: Clark, Otavio, et al.
Publicado: (2002)

Relationship between Sinonasal Anatomical Variations and Symptom Severity in Patients with Chronic Rhinosinusitis
por: Shirama, Yakubu Bababa, et al.
Publicado: (2020)

Management of anaemia in CKD—the relative importance of erythropoietin and iron
por: Agarwal, Rajiv
Publicado: (2011)

Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach to Management of Anaemia in Chronic Kidney Disease
por: Yugavathy, Nava, et al.
Publicado: (2023)

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.
por: Barosi, G., et al.
Publicado: (1998)

Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis
por: Evans, Marie, et al.
Publicado: (2020)

Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis
por: Vankar, Sameer G., et al.
Publicado: (2014)

Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study.
por: Cascinu, S., et al.
Publicado: (1993)

Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.
por: Thews, O., et al.
Publicado: (1998)

Anaemia at discharge from the intensive care unit is associated with an inappropriate erythropoietin response
por: Bateman, A, et al.
Publicado: (2005)

The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.
por: Joiner, B., et al.
Publicado: (1993)

Response of patients with sickle cell anaemia and end-stage renal disease to erythropoietin treatment
por: Zumrutdal, Aysegul
Publicado: (2010)

Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
por: Hanna, Ramy M., et al.
Publicado: (2020)

Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia
por: Duman, Neval, et al.
Publicado: (2014)

Does erythropoietin slow progression of chronic kidney disease?
por: Nasri, Hamid, et al.
Publicado: (2013)

Erythropoietin (EPO) in acute kidney injury
por: Moore, Elizabeth, et al.
Publicado: (2011)

Implications of anaemia and response to anaemia treatment on outcomes in patients with cirrhosis
por: Rashidi-Alavijeh, Jassin, et al.
Publicado: (2023)

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)

Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives
por: Santos, Elton Jonh Freitas, et al.
Publicado: (2020)

Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial
por: Aoun, Mabel, et al.
Publicado: (2022)

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
por: Kalra, Philip A., et al.
Publicado: (2016)

Anaemia and pregnancy: Anaesthetic implications
por: Grewal, Anju
Publicado: (2010)

Age-related pattern and monocyte-acquired haemozoin associated production of erythropoietin in children with severe malarial anaemia in Ghana
por: Abugri, James, et al.
Publicado: (2014)

Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients
por: Malyszko, Jolanta, et al.
Publicado: (2017)

Erythropoietin in bone homeostasis—Implications for efficacious anemia therapy
por: Lappin, Katrina M., et al.
Publicado: (2021)

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021)

Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study
por: Iso, Takashi, et al.
Publicado: (2022)

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
por: Macdougall, Iain C., et al.
Publicado: (2014)

Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial
por: Chen, Lin, et al.
Publicado: (2016)

Delayed surgical debridement in pediatric open fractures: a systematic review and meta-analysis
por: Ibrahim, Talal, et al.
Publicado: (2014)

Effects of Angiotensin II on Erythropoietin Production in the Kidney and Liver
por: Yasuoka, Yukiko, et al.
Publicado: (2021)

Effects of Adjuvant Androgen on Anemia and Nutritional Parameters in Chronic Hemodialysis Patients Using Low-dose Recombinant Human Erythropoietin
por: Lee, Myeung Su, et al.
Publicado: (2002)

Challenging patient phenotypes in the management of anaemia of chronic kidney disease
por: Pramod, Sheena, et al.
Publicado: (2021)

Impaired erythropoietin synthesis in chronic kidney disease is caused by alterations in extracellular matrix composition
por: Olmos, Gemma, et al.
Publicado: (2017)

Anti-erythropoietin antibody levels and its association with anaemia in different strains of semi-immune mice infected with Plasmodium berghei ANKA
por: Helegbe, Gideon Kofi, et al.
Publicado: (2013)

Successful application of roxadustat in the treatment of patients with anti-erythropoietin antibody-mediated renal anaemia: a case report and literature review
por: Cai, Ke-Dan, et al.
Publicado: (2021)

Interpretation of Erythropoietin and Haemoglobin Levels in Patients with Various Stages of Chronic Kidney Disease
por: Panjeta, Mirsad, et al.
Publicado: (2017)

Anaemia and acute kidney injury: the tip of the iceberg?
por: Lombardi, Yannis, et al.
Publicado: (2020)

Erythropoietin, Fibroblast Growth Factor 23, and Death After Kidney Transplantation
por: Eisenga, Michele F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_areooc0qc7nn0t7bgosd6jbk97